Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT00104182

Public ClinicalTrials.gov record NCT00104182. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy and Safety Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening as Add-on to Oral Antidiabetic Drug(s) in Patients With Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment with oral antidiabetic drugs in patients with Type 2 diabetes.

Study identification

NCT ID
NCT00104182
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
503 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2005
Primary completion
Jan 31, 2006
Completion
Jan 31, 2006
Last update posted
Jan 29, 2017

2005 – 2006

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
29
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35235
Novo Nordisk Investigational Site Mesa Arizona 85205
Novo Nordisk Investigational Site Phoenix Arizona 85029
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site Concord California 94520
Novo Nordisk Investigational Site Fullerton California 92835
Novo Nordisk Investigational Site La Jolla California 92037
Novo Nordisk Investigational Site Los Angeles California 90057
Novo Nordisk Investigational Site Orange California 92869
Novo Nordisk Investigational Site Poway California 92064
Novo Nordisk Investigational Site Denver Colorado 80220
Novo Nordisk Investigational Site Lake Mary Florida 32746
Novo Nordisk Investigational Site Springfield Illinois 62711
Novo Nordisk Investigational Site Fall River Massachusetts 02721
Novo Nordisk Investigational Site Waltham Massachusetts 02453
Novo Nordisk Investigational Site Jefferson City Missouri 65109
Novo Nordisk Investigational Site Las Vegas Nevada 89030
Novo Nordisk Investigational Site Lewiston New York 14092
Novo Nordisk Investigational Site Williamsville New York 14221
Novo Nordisk Investigational Site Grand Forks North Dakota 58201
Novo Nordisk Investigational Site Cincinnati Ohio 45291
Novo Nordisk Investigational Site Dayton Ohio 45406
Novo Nordisk Investigational Site Connellsville Pennsylvania 15425
Novo Nordisk Investigational Site Lancaster Pennsylvania 17601
Novo Nordisk Investigational Site Norristown Pennsylvania 19401
Novo Nordisk Investigational Site Greer South Carolina 29651
Novo Nordisk Investigational Site Conroe Texas 77384
Novo Nordisk Investigational Site Killeen Texas 76543
Novo Nordisk Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00104182, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 29, 2017 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00104182 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →